Enterprise Value

350.7M

Cash

44.76M

Avg Qtr Burn

-15.66M

Short % of Float

10.53%

Insider Ownership

11.48%

Institutional Own.

61.68%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PRGN-2009 OTS AdenoVerse™ +/- Pembrolizumab Details
Cancer, Solid tumor/s, Squamous cancers

Phase 2

Update

Phase 2

Initiation

PRGN-2012 AdenoVerse™ Details
Recurrent respiratory papillomatosis, Cancer

Phase 1/2

Update

PRGN-3005 UltraCAR-T® Details
Ovarian cancer, Cancer

Phase 1b

Data readout

PRGN-3006 UltraCAR-T® Details
Cancer, Acute myeloid leukemia

Phase 1b

Data readout

PRGN-3007 UltraCAR-T® Details
Cancer, Blood cancer, Solid tumor/s

Phase 1

Data readout

AG019 ActoBiotics™ Details
Type 1 diabetes, Diabetes

Failed

Discontinued